Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Daxor Corporation is a medical instruments & supplies business based in the US. Daxor Corporation shares (DXR) are listed on the NYSE MKT and all prices are listed in US Dollars.
|Latest market close||$10.71|
|52-week range||$8.58 - $15.46|
|50-day moving average||$11.23|
|200-day moving average||$10.42|
|Wall St. target price||$22.00|
|Dividend yield||$0.03 (0.27%)|
|Earnings per share (TTM)||$0.07|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-2.64%|
|1 month (2021-09-28)||-2.90%|
|3 months (2021-07-28)||19.40%|
|6 months (2021-04-28)||8.73%|
|1 year (2020-10-27)||-27.39%|
|2 years (2019-10-25)||17.18%|
|3 years (2018-10-26)||127.87%|
|5 years (2016-10-27)||31.90%|
Valuing Daxor Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Daxor Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Daxor Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 145x. In other words, Daxor Corporation shares trade at around 145x recent earnings.
|Gross profit TTM||$264,440|
|Return on assets TTM||-2.1%|
|Return on equity TTM||2.29%|
|Market capitalisation||$42.7 million|
TTM: trailing 12 months
There are currently 12,875 Daxor Corporation shares held short by investors – that's known as Daxor Corporation's "short interest". This figure is 0.1% up from 12,859 last month.
There are a few different ways that this level of interest in shorting Daxor Corporation shares can be evaluated.
Daxor Corporation's "short interest ratio" (SIR) is the quantity of Daxor Corporation shares currently shorted divided by the average quantity of Daxor Corporation shares traded daily (recently around 18659.420289855). Daxor Corporation's SIR currently stands at 0.69. In other words for every 100,000 Daxor Corporation shares traded daily on the market, roughly 690 shares are currently held short.
However Daxor Corporation's short interest can also be evaluated against the total number of Daxor Corporation shares, or, against the total number of tradable Daxor Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Daxor Corporation's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Daxor Corporation shares in existence, roughly 0 shares are currently held short) or 0.0098% of the tradable shares (for every 100,000 tradable Daxor Corporation shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Daxor Corporation.
Find out more about how you can short Daxor Corporation stock.
We're not expecting Daxor Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Daxor Corporation's shares have ranged in value from as little as $8.58 up to $15.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Daxor Corporation's is -1.1635. This would suggest that Daxor Corporation's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Daxor Corporation has bucked the trend.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.